The fact that both HPV-positive and -negative tumor cells responded similarly to AZD 1775 implicates that the mutational status of p53, rather than the status of HPV infection, is responsible for preferential sensitivity to Wee1 inhibitors16. Here, WEE1 is linked to neoplasm.